In the cancer field, rare stem cells are thought essential to the onset, perpetuation and recurrences of human cancers. To date, cancer stem cells have been identified as causal in some malignancies, such as acute myelogenous leukemia, chronic myelogenous leukemias, B-cell lymphoblastic leukemias and possibly solid tumors. 1 The cancer stem cells based on this hypothesis are both necessary and sufficient for cancer growth and can be expanded in culture, unlike the cancer cells themselves. Therefore, an overriding goal in oncology has become the identification and eradication of the rare stem cells capable of sustained growth of the neoplasmFin lieu of the cancer itself. Ideally, those stem cells might be localizable in special reservoirs that would be targeted for therapeutics.
The strongest support for the cancer stem cell hypothesis has come from studies of acute myelogenous leukemia. A key study, for example, showed that only a small fraction of cells from human acute myelogenous leukemia, when transplanted into mice, managed to sustain tumor growth. 2 This xenotransplant study was consistent with the clinical success of bone marrow (BM) transplants for acute myelogenous leukemia based on the rationale that a few hematopoietic cancer stem cells in the marrow are responsible for tumor growth. Therefore, BM transplantation would likely decrease the burden of cancer stem cells with the BM transplant. However, a provocative article by Kelly and co-workers (2007) challenges the cancer stem cell hypothesis. 3 It questions the mouse xenotransplant study by arguing that few human cancer cells could survive transplantation into mice to promote tumor growth, not because of rare cancer stem cells, but because few human cancer cells could survive in the mouse milieu. A better murine test of the cancer stem cell hypothesis, according to the authors, would come from mouse to mouse transplants as opposed to xenotransplants (human cancer cells into mice). Indeed, when they undertook a study of mouse cancer cells of diverse lineages into mice, they found that diverse murine cancer cells survived the transplantation into another murine host and there induced growth of lymphoid and myeloid malignancies. The authors argued that the cancer stem cell hypothesis needed more rigorous testing in different models.
For almost a decade, our laboratory has focused on cellular therapies for diabetes and other disorders. But the findings we report here could be marshaled for another purpose, to pave the way for a rigorous test of the stem cell hypothesis of cancerFin humans. Our findings suggest that splenectomy, a low-risk surgical procedure to remove a nonessential organ, would be beneficial for certain patients with acute lymphocytic leukemia (ALL) of T-cell lineage, which aberrantly expressed Hox11. Splenectomy could immediately be tried not only as a test of the cancer stem cell hypothesis, but even more importantly as a therapeutic option for one subtype of ALL tumors: those expressing the highly conserved transcription factor Hox 11. To our knowledge, splenectomy as a treatment for Hox11 expressing ALL tumors has not been performed.
We hypothesize that the source of Hox11-expressing ALL is in the spleen, based on our findings in an animal model 4 and our findings in humans, which are reported here. The spleen, but no other organs of normal adults, of all ages, holds a reservoir of stem cells that abundantly express the Hox11 transcription factor. What is unusual about finding this reservoir in the spleen is that the prevailing dogma among developmental biologists is that Hox 11 (also known as Tlx-1) is not expressed after birth. Developmental biologists have shown that, during embryogenesis, Hox11 activates a cascade of genes controlling cell fate and differentiation, but ceases after birth. 5, 6 A decade before investigations by developmental biologists, cancer biologists had identified Hox 11 as a proto-oncogene in humans by virtue of its dysregulation or aberrant expression in certain types of T-cell ALL and in many forms of pediatric neural tumors. 7 Hox 11 has prognostic importance in adults with T-cell ALL and offers a molecular approach to risk classification of adults with this disease. Thus far, the source of cancer stem cells for ALL subtype with Hox11 expression has not yet been identified. It is clear, however, that the source is unlikely in the BM because clinical data suggest that the application of intensified BM transplants have not improved the rates of cure and instead have increased mortality. Like most cancers, ALL cells have limited proliferative capacity in vitro, suggesting that these cells are not the elusive progenitors in vivo that maintain the disease.
Here we report our investigation of whether the spleen of adult humans contains candidate stem cells with continuous expression of the Hox11 oncogene. We obtained normal human spleens, produced during harvesting procedures for organ donation. The reasons for death were diverse (for example, automobile injury, cerebral hemorrhage, heart attack) but they qualified for organ donation. For these studies, frozen spleen tissue from 13 males and 17 females was processed in duplicate to prepare RNA from two separate tissue slices for reverse transcription (RT)-PCR analysis. In addition, control RNA was prepared from diverse donors with samplings of the BM, kidney, liver and tonsil samples from human donors. Tissue samples were procured from the National Disease Research Interchange (NDRI) and were of similar quality, consistently handled and stored prior to analysis.
Using RT-PCR analysis and DNA quantitative analysis, human spleen samples were prepared from 30 male and female spleen donors. The RT-PCR showed robust expression of Hox11 between and within donor spleen samples. Multiple sampling regions of each human spleen were identified and processed separately. Hox11 expression in the spleen was very apparent (Figure 1a) . The Hox11 expression in the human spleen was restricted to this organ and not other human lymphoid or nonlymphoid organs. Thus, Hox11 expression is plentiful in the human spleen, as compared with negligible expression in BM, kidney, liver and tonsil (Figure 1a) . The RT-PCR primer binds specifically to the Hox11 gene as shown by the appearance of a single band of approximately 220 base pairs (bp) long and the lack of gene expression in a negative control (C) where no RNA template was added to the binding reaction. We observed no additional products formed at any other bp length as shown in the DNA retardation gel with DNA bp markers (M) with either the Hox11 or b-actin-specific primer.
To determine if the level of Hox11 expression in human spleen samples varied by age and gender of humans, we performed quantitative analysis of the DNA products formed by RT-PCR. Quantitative analysis was performed with Quant-iT PicoGreen dsDNA fluorescent probe from two independent tissue samples from the same donor. The level of gene expression in the spleen was consistently high within the same donor and between donors. Its expression remained high and did not vary by age (Figure 1b) . We observed higher levels in patients with type II diabetes (Figure 1b) . The three known diabetic donors had among the highest level of Hox11 expression, consistent with a mouse literature suggesting insulin secreting beta cell precursor reside in the spleen and expand with select peripheral tissue damage. Quantitative analysis of Hox11 spleen expression by gender showed no statistically significant gender difference (Figure 1c) .
A trait of stem cells is expansion in tissue culture. Unlike differentiated or committed cell populations or even cancer cells, expansion in tissue culture is a unique trait of a precursor stem cell. Stem cells possess self-renewal and Hox11 transfection itself can immortalize embryonic precursors and stem cells with partial hematopoietic potential. 8 Using isolated human spleen cells with enrichment by negative depletion of committed hematopoietic CD45 cell populations, we tested whether these human Hox11-positive cells show autonomous proliferation. We observed brisk proliferation and persistently abundant Hox11 expression in tissue culture of the newly identified human stem cells of the spleen. Cell culture with expansion could be maintained beyond 2 months in vitro (Figure 1d ). This suggests the potential for expansion of this unique population of Hox11-positive cells is maintained. To our knowledge, expression of Hox11 has not been observed in any other human tissue Letters to the Editor from normal adults and this study re-confirms this observation upon surveys of human tissues. Since expansions in vitro are a trait of stem cells, not differentiated hematopoietic or other differentiated cell populations, this human proliferative potential is consistent with the Hox11 expression and a stem cell signature.
The observations that Hox11 is abundantly and uniquely expressed in normal human spleen and its expression extends late into the aging process are of interest. First, the data suggest that the adult human spleen may have, similar to the mouse, a reservoir of well-regulated stem cells with multi-lineage potential. Second, the adult human spleen could also house the progenitor stem cells that, with transformation, could be a precursor for some forms of cancer such as Hox11-expressing T-ALL or pediatric neuronal tumors. Thus, our findings in normal humans could provide the rationale for splenectomy as a test of the cancer stem hypothesis in a certain patients with ALL. Finally, our findings suggest that splenectomy would be a lowrisk therapeutic procedure for adults and pediatric patients with a poor prognosis and for whom there are few treatment options.
